Akebia leaps, after agreeing termination deal with Otsuka over vadadustat

2 July 2022

The original news that Japan’s Otsuka (TYO: 4578) had decided to give back rights to vadadustat to Akebia Therapeutics (Nasdaq: AKBA) caused the US firm’s shares to slump. However, the disclosure that, as part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million saw its stock leap as much as 40% to $0.50 pre-market on Friday.

Under the terms of their agreement, Akebia received $265 million in committed funds from Otsuka plus development and commercial milestones, representing a total transaction value that could have exceeded $1 billion.

As a result of the termination of the agreements, Akebia is regaining the rights from Otsuka for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in the USA, Europe, China, Russia, Canada, Australia, the Middle East, and certain other territories.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK